Dynavax Technologies Balance Sheet Health
Financial Health criteria checks 6/6
Dynavax Technologies has a total shareholder equity of $494.2M and total debt of $260.8M, which brings its debt-to-equity ratio to 52.8%. Its total assets and total liabilities are $918.4M and $424.3M respectively. Dynavax Technologies's EBIT is $8.1M making its interest coverage ratio -0.3. It has cash and short-term investments of $613.7M.
Key information
52.77%
Debt to equity ratio
US$260.77m
Debt
| Interest coverage ratio | -0.3x |
| Cash | US$613.73m |
| Equity | US$494.16m |
| Total liabilities | US$424.29m |
| Total assets | US$918.45m |
Recent financial health updates
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Jan 24
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Recent updates
Dynavax Technologies: A Dip To Accumulate
Aug 11Dynavax Technologies Corporation Reported A Surprise Loss, And Analysts Have Updated Their Forecasts
May 08We Think Dynavax Technologies' (NASDAQ:DVAX) Profit Is Only A Baseline For What They Can Achieve
Mar 04Dynavax Technologies: A Post-Earnings Assessment With Growing Market Share
Mar 03Dynavax Technologies: Time To Refocus On Former Cash Cow CpG1018
Feb 05Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Jan 24Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12
HEPLISAV-B And New Vaccine Trials Set To Skyrocket Revenue And Market Share
Strong HEPLISAV-B sales and market optimism indicate potential for revenue growth and market share expansion in the adult hepatitis B vaccine sector.Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Financial Position Analysis
Short Term Liabilities: DVAX's short term assets ($785.7M) exceed its short term liabilities ($118.2M).
Long Term Liabilities: DVAX's short term assets ($785.7M) exceed its long term liabilities ($306.1M).
Debt to Equity History and Analysis
Debt Level: DVAX has more cash than its total debt.
Reducing Debt: DVAX's debt to equity ratio has reduced from 308.2% to 52.8% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable DVAX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: DVAX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 32.1% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/08 12:42 |
| End of Day Share Price | 2025/10/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Dynavax Technologies Corporation is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Douglas Buchanan | Citizens JMP Securities, LLC |
| Jason Butler | Citizens JMP Securities, LLC |